

The New Mount Sinai Campaign

Delivering Transformational Growth
Across the Health System by 2024



WE CANNOT WAIT

The Time for Philanthropy is **NOW**

The Mount Sinai Health System has embarked on a new major campaign that will cover the comprehensive needs of our institution, from research labs, clinical facilities, and faculty recruitment to infrastructure, the modernization of hospitals, and the buildout of ambulatory facilities.

This is the first campaign since the formation of the Mount Sinai Health System in 2013, when The Mount Sinai Hospital, Mount Sinai Queens, and the Icahn School of Medicine at Mount Sinai combined with the former Continuum Health Partners and its five hospitals to become one of the largest health systems in the New York region.

The campaign will raise funds not just for research, but will also strengthen and redesign infrastructure that connects the scientific and clinical components of our health system.

1st
Comprehensive
Campaign for
Mount Sinai
Health System

\$2.0 Billion
GOAL

2017-2020
EARLY NUCLEUS
PHASE

2020-2024
EXTENDED
CAMPAIGN
PHASE

“ *We are at an extraordinary point in time.*”

The revolution in biology is leading to possibilities in therapeutics that we never dreamed of. Mount Sinai has already made the investment that translates research from laboratory findings into revolutionary treatments. In order for Mount Sinai to continue to be at the forefront of the explosion of scientific discovery, *it is a necessity for philanthropy to be the engine to help us achieve even greater breakthroughs in science and medicine and the work it will enable.*

We are an integrated health care system, not a series of independent hospitals. To enhance our system and make sure the Mount Sinai brand stands for equivalent care in all its locations we need to upgrade spaces and allow services to be streamlined so that the system is able to care for patients throughout the New York area maximizing on the strengths of our eight member hospitals.

To achieve our goals both our science and our health care delivery need more space. Right now, we don't have enough room to accommodate our next generation of scientists. This thwarts our future and the ability for Mount Sinai to continue as the leader it has been. Additionally, we must *fund strategic investments in hospital and ambulatory infrastructure to help us enhance the connectivity of the Health System, enabling us to deliver the highest quality care across the greater New York area.*

Last but certainly not least, the center of our new campaign is our people. It is paramount that Mount Sinai better meet the needs of the communities it serves. Our goal is for patients to have more control and more cost-effective treatments, that ultimately promote wellness. And we need to accomplish all this in the context of the enormous financial pressures in health care today. *Our campaign is centered* on moving from a fee-for-service model of care to one that focuses on providing value and measures the quality of care provided to our patients.

We anticipate that our campaign will be transformational, a game changer that is as successful if not more so than the campaign we undertook 10 years ago. We are steering a course to not only advance medicine, but to raise the quality of care to new heights.”



KENNETH L. DAVIS, MD
PRESIDENT AND CHIEF EXECUTIVE OFFICER
MOUNT SINAI HEALTH SYSTEM

A Message from the CEO



**WE
CANNOT
WAIT**

“The timing of this new campaign is critical. Achieving our goals will revolutionize the way diseases are diagnosed and treated and the way patients are cared for—ultimately unlocking how we prevent diseases. *We have the chance to transform health care right now.*”

DENNIS S. CHARNEY, MD
ANNE AND JOEL EHRENKRANZ DEAN
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PRESIDENT FOR ACADEMIC AFFAIRS
MOUNT SINAI HEALTH SYSTEM



WE CAN REINVENT MEDICINE

5

GUIDING
PRINCIPLES



Leverage the size and excellence of the Mount Sinai Health System



Establish unrivaled excellence in medical and graduate education



Anticipate and fund new areas of research that will result in the discovery of novel approaches to disease diagnosis and treatment



Invest further in current areas of excellence



Power an “Engine of Discovery” to create more intellectual property, more collaborations with industry, and more Mount Sinai companies



“We are at a crossroads with what’s going on in research, biology, and technology—a positive inflection point. Mount Sinai has an extraordinary opportunity to chart its own course.”

Richard A. Friedman
Co-Chairman, Boards of Trustees
Chairman, Development Committee
Mount Sinai Health System



“The health system has had extraordinary growth in quality and results over the past decades. In order to sustain this growth, we need to redouble both our charitable funds and our focus on health care professionals.”

James S. Tisch
Co-Chairman, Boards of Trustees
Mount Sinai Health System



“The campaign will help us push forward with innovative efforts like combining research and incubation facilities that will attract the biotech industry to work with us on delivering new treatments.”

Peter W. May
Chairman Emeritus, Boards of Trustees
Mount Sinai Health System

WE CAN HARNESS THE FUTURE OF MEDICINE TODAY

The campaign will benefit both the System hospitals and the Icahn School of Medicine.

5 PRIORITIES for investment:



CLINICAL AND RESEARCH PROGRAMS



RECRUITING TALENT



TECHNOLOGY AND BIOINFORMATICS



INNOVATIVE MEDICAL EDUCATION



REDESIGNING INFRASTRUCTURE

STRATEGIC PRIORITIES



WE CAN TRANSFORM HEALTH CARE

STRATEGIC PRIORITIES *holistic health*

Brain

Five of the top 10 causes of disease burden worldwide are brain disorders: depression, stroke, dementia, addiction, and psychosis. The Friedman Brain Institute (FBI) has made each of these a priority area and is approaching them in a multidisciplinary and innovative way. As a leader in understanding the underlying genetics of neurological disease, we are actively translating this neurobiology into new targeted therapies for such diseases as Parkinson's, Alzheimer's, autism, and even depression and addiction.

Cancer

The Tisch Cancer Institute (TCI) at Mount Sinai, a National Cancer Institute-designated cancer center, is a leading innovator in research, clinical care, early diagnosis, and prevention. In partnership with Mount Sinai scientists across disciplines, such as immunology, precision medicine, and bioinformatics, we decipher cancer biology at the molecular level and identify mechanisms underlying the suppression of anti-tumor immunity. By developing preclinical models and translating discoveries into novel targeted therapeutics, we are able to control and cure the most complex cancers.

Children's Health

Each year, more than 110,000 babies and children are cared for at Mount Sinai. Our patients represent our diverse community, and half of these children are uninsured or underinsured. The Department of Pediatrics and the Mindich Child Health and Development Institute are changing the landscape of children's health by using new genomic tools to predict, prevent, and diagnose disease, developing new therapeutics, and addressing the social determinants of health to ensure a healthy future for all children.

Diabetes

Mount Sinai is home to one of the first diabetes treatment and research centers in the world and has a long history of innovations in care. Our world-renowned experts deliver personalized care to over 200,000 patients with type 1 and type 2 diabetes at 25 locations throughout the five boroughs. With strengths in both scientific discovery and patient care, we are making advancements in artificial pancreas and beta cell regeneration research, which is changing the landscape of diabetes management throughout New York City, across the country, and around the globe.

Drug Discovery

Advancements in our understanding of the mechanisms of disease, along with the development of novel tools and technologies, has created unprecedented opportunities for the exploration of next generation therapeutics. Scientists and technologists in our Drug Discovery Institute are working across promising areas of discovery with the goal of addressing urgent and unmet medical needs, ultimately impacting outcomes for patients worldwide.

Heart

On every front in the fight against cardiovascular disease—from prevention to research to care—our physicians and scientists at Mount Sinai Heart aim to establish a global standard of excellence that puts the patient first. Philanthropic investments in all aspects of eliminating cardiovascular disease have allowed Mount Sinai to impact the lives of countless patients and their families.

Immunology

Mount Sinai is redefining medicine and discovering new approaches to today's most pressing health issues by unlocking the mysteries of the human immune system. The Precision Immunology Institute is playing a leading role in the development of the Human Cell Atlas, aiming to understand disease at the cellular and molecular level. Better classification of disease will help the development of precise therapies, increasing the likelihood of finding definitive cures.

Precision Medicine

Individualized health care based on unique biological and environmental factors is fundamental to our work. Data science, genomics, and artificial intelligence are changing how we care for people. In addition to genetics, our work identifies complex nutritional, chemical, and social environmental exposures. Our teams are testing and customizing novel therapies and innovative interventions, using our genomic medicine expertise for the prevention, earliest diagnosis, and most effective treatment of disease. We are bringing the future of health care to our patients now—faster than has ever been possible.



**WE
CANNOT
WAIT**

The Mount Sinai Health System comprises eight hospitals and the Icahn School of Medicine at Mount Sinai:

Mount Sinai Beth Israel + Mount Sinai Brooklyn + The Mount Sinai Hospital + Mount Sinai Queens + Mount Sinai St. Luke's + Mount Sinai West + New York Eye and Ear Infirmary of Mount Sinai + South Nassau Communities Hospital

STRATEGIC PRIORITIES *infrastructure*

The new campaign will fund strategic investments in infrastructure across the Health System. These projects will enable Mount Sinai to better serve the needs of our large and diverse patient population and to advance our basic, clinical, and translational research efforts.

Capital Improvement Projects INCLUDE:

Creating the Hamilton and Amabel James Center for Artificial Intelligence and Human Health to Drive Innovation in Data Science, Artificial Intelligence, Bioengineering, and Precision Medicine

Improving Emergency & Intensive Care Facilities

Building a New Mount Sinai Beth Israel Hospital

Modernizing Catherization Labs and Enhancing Capabilities at Mount Sinai Heart

Broadening Pediatric Critical Care Facilities Including the New NICU at Mount Sinai West and PCICU at The Mount Sinai Hospital

Expanding Ambulatory Services at 432 West 58th Street at Mount Sinai West

Optimizing Care at Mount Sinai Union Square

Expanding the Surgical Platforms at Mount Sinai St. Luke's and Mount Sinai West

Enhancing the Patient Experience by Upgrading Inpatient Units

Creating Specialized Inpatient Units for Cancer Patients



**WE
CANNOT
WAIT**

WE CAN PREVENT HEART DISEASE
THE WORLD WE CAN EMPOWER
PATIENTS WE CAN FIND ALZHEIMER
BREAKTHROUGHS WE CAN DRIVE
INNOVATION WE CAN TREAT EVERY
CHILD WE CAN FIGHT CANCER
LIVES **WE CANNOT WAIT** WE CAN
CONQUER DISEASE WE CAN DO
SOMETHING TOGETHER WE CAN
ADVANCE PRECISION MEDICINE

Mark Kostegan, FAHP
Chief Development Officer
Senior Vice President for Development
Mount Sinai Health System
Mark.Kostegan@mountsinai.org
212-659-1568

giving.mountsinai.org



**WE
CANNOT
WAIT**

